MedTrace Logo

Study Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine

NCT02079207 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 767

Last updated 2016-01-27

No results posted yet for this study

Summary

This study will assess the Immunogenicity and safety of 13-valent Pneumococcal Conjugate Vaccine compared with 23-valent Pneumococcal Polysaccharide Vaccine. All participants should be naïve of Pneumococcal vaccine.

Conditions

  • Pneumococcal Infections

Interventions

BIOLOGICAL

NBP606

13-valent peumococcal conjugate vaccine(13vPnC)

BIOLOGICAL

Prodiax-23

23-valent peumococcal polysaccharide vaccine(23vPS)

Sponsors & Collaborators

  • SK Chemicals Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • MYUNGDON OH, MD · Seoul National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2014-10-31
Completion
2015-03-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02079207 on ClinicalTrials.gov